Inhibikase Therapeutics (IKT) Gains from Investment Securities (2020 - 2025)
Historic Gains from Investment Securities for Inhibikase Therapeutics (IKT) over the last 6 years, with Q3 2025 value amounting to $27.2 million.
- Inhibikase Therapeutics' Gains from Investment Securities rose 873843.38% to $27.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.2 million, marking a year-over-year increase of 873843.38%. This contributed to the annual value of $1.4 million for FY2020, which is N/A changed from last year.
- According to the latest figures from Q3 2025, Inhibikase Therapeutics' Gains from Investment Securities is $27.2 million, which was up 873843.38% from $25.8 million recorded in Q2 2025.
- Inhibikase Therapeutics' Gains from Investment Securities' 5-year high stood at $27.2 million during Q3 2025, with a 5-year trough of $18039.0 in Q1 2024.
- Moreover, its 5-year median value for Gains from Investment Securities was $137354.0 (2023), whereas its average is $4.7 million.
- In the last 5 years, Inhibikase Therapeutics' Gains from Investment Securities crashed by 9677.94% in 2021 and then soared by 11813934.25% in 2025.
- Over the past 5 years, Inhibikase Therapeutics' Gains from Investment Securities (Quarter) stood at $29839.0 in 2021, then skyrocketed by 156.88% to $76651.0 in 2022, then grew by 13.07% to $86669.0 in 2023, then surged by 255.42% to $308039.0 in 2024, then skyrocketed by 8738.43% to $27.2 million in 2025.
- Its Gains from Investment Securities was $27.2 million in Q3 2025, compared to $25.8 million in Q2 2025 and $21.3 million in Q1 2025.